{
  "$schema": "folio-library-entry/v1",
  "id": "10665-268219",
  "blocks": [
    {
      "id": "library/10665-268219/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Bulletin 2000 Feedback",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/sec-000-bulletin-2000-feedback.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-268219/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Adverse events monitoring as a routine component of vaccine clinical trials: evidence from the WHO Vaccine Trial Registry",
      "pageStart": 1,
      "pageEnd": 2,
      "target": "../sections/sec-001-adverse-events-monitoring-as-a-routine-component.md",
      "narrative": null,
      "content": "as a routine component\nof vaccine clinical trials:\nevidence from the WHO\nVaccine Trial Registry\nThe February 2000 Bulletin Round Table\nDiscussion on vaccine adverse events\nincludes a commentary by Clemens on\nevaluation of vaccine safety before and\nafter licensure (1). Clemens emphasizes that\nsample sizes in Phase 1–3 vaccine clinical\ntrials are generally too small to assess the\npotential of vaccines to produce rare side-\neffects. Another problem in evaluating\nadverse events in clinical trials is that the\npopulation studied is usually healthy and\nthusmaydifferfromthepopulationroutinely\nadminist",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A 2000 Bulletin feedback piece reporting on how adverse events following immunization were monitored in vaccine trials recorded in the WHO Vaccine Trial Registry. It notes that early-phase trials are too small to detect rare side-effects, defines adverse events according to Good Clinical Practice guidelines, and reviews 68 trials of vaccines against diseases such as cholera, hepatitis B, measles and typhoid. A closing table classifies the adverse events monitored, from local and mild systemic reactions to death, by short-term versus long-term follow-up.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-268219/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Number of vaccine trials conducting short-term (<4 weeks) and long-term (≥ 4 weeks) monitoring of adverse events following immunization (AEFI), WHO Vaccine Trial Registry, 1987–1999",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table shows how many vaccine trials in the WHO Vaccine Trial Registry (1987–1999) conducted short-term (<4 weeks) and long-term (≥ 4 weeks) monitoring of adverse events following immunization, and how many reported details on the types of AEFI, with percentages of the 68 trials.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-268219/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Number of trials reporting adverse events following immunization (AEFIs) in short-term and long-term monitoring, WHO Vaccine Trial Registry, 1987–99",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table shows the number of trials in the WHO Vaccine Trial Registry (1987–99) reporting each type of adverse event following immunization (none, local, mild systemic, immune-mediated, severe systemic toxicity, other, death), separately for short-term (< 4 weeks, n = 17) and long-term (≥ 4 weeks, n = 4) monitoring.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
